4-乙氧基萘-1-磺酰氯 | 91222-55-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-乙氧基萘-1-磺酰氯
• 英文名称: 4-ethoxy-naphthalene-1-sulfonyl chloride
• 英文别名: 4-Aethoxy-naphthalin-1-sulfonylchlorid；4-Ethoxynaphthalene-1-sulfonyl chloride
• CAS: 91222-55-8
• 化学式: C₁₂H₁₁ClO₃S
• mdl: MFCD09044337
• 分子量: 270.737
• InChiKey: UMUUBVDEZWLVED-UHFFFAOYSA-N

物化性质

• 沸点：
  408.1±20.0 °C(Predicted)
• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-乙氧基萘-1-磺酰氯 在 吡啶 、 水 、 sodium hydroxide 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 2.0h， 生成 5-((4-ethoxynaphthalene)-1-sulfonamido)-2-fluorobenzoic acid
  参考文献：
  名称：

  Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor

  摘要：

  Fatty acid binding protein 4 (FABP4) and fatty acid binding protein 5 (FABP5) are mainly expressed in adipocytes and/or macrophages and play essential roles in energy metabolism and inflammation. When FABP4 function is diminished, FABP5 expression is highly increased possibly as a functional compensation. Dual FABP4/5 inhibitors are expected to provide beneficial synergistic effect on treating diabetes, atherosclerosis, and inflammation-related diseases. Starting from our previously reported selective FABP4 inhibitor 8, structural biology information was used to modulate the selectivity profile and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. Two compounds A16 and B8 were identified to show inhibitory activities against both FABP4/5 and good selectivity over FABP3, which could also reduce the level of forskolin-stimulated lipolysis in mature 3T3-L1 adipocytes. Compared with compound 8, these two compounds exhibited better anti-inflammatory effects in lipopolysaccharide-stimulated RAW264.7 murine macrophages, with decreased levels of pro-inflammatory cytokines TNF alpha and MCP-1 and apparently inhibited IKK/NF-kappa B pathway.

  DOI：

  10.1016/j.bmc.2019.07.031
• 作为产物：
  描述：

  sodium 1-naphthol-4-sulfonate 在 氯化亚砜 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 4-乙氧基萘-1-磺酰氯
  参考文献：
  名称：

  Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor

  摘要：

  Fatty acid binding protein 4 (FABP4) and fatty acid binding protein 5 (FABP5) are mainly expressed in adipocytes and/or macrophages and play essential roles in energy metabolism and inflammation. When FABP4 function is diminished, FABP5 expression is highly increased possibly as a functional compensation. Dual FABP4/5 inhibitors are expected to provide beneficial synergistic effect on treating diabetes, atherosclerosis, and inflammation-related diseases. Starting from our previously reported selective FABP4 inhibitor 8, structural biology information was used to modulate the selectivity profile and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. Two compounds A16 and B8 were identified to show inhibitory activities against both FABP4/5 and good selectivity over FABP3, which could also reduce the level of forskolin-stimulated lipolysis in mature 3T3-L1 adipocytes. Compared with compound 8, these two compounds exhibited better anti-inflammatory effects in lipopolysaccharide-stimulated RAW264.7 murine macrophages, with decreased levels of pro-inflammatory cytokines TNF alpha and MCP-1 and apparently inhibited IKK/NF-kappa B pathway.

  DOI：

  10.1016/j.bmc.2019.07.031

文献信息

• Modulators of Rho C activity
  申请人：——

  公开号：US20030171341A1

  公开（公告）日：2003-09-11

  Compounds of formula 1 modulate the activity of Rho C: 1 wherein R is a direct bond, lower alkylene, —C(O)NH—, or —NHC(O)—; Ar is aryl or heteroaryl, substituted with R 7 , R 8 , R 9 , and R 10 , wherein R 7 , R 8 , and R 9 are each independently H, halo, lower alkyl, OH, lower alkoxy, and R 10 is H, halo, lower alkyl, OH, lower alkoxy, or forms a ring with R 1 ; R 1 is H, lower alkyl, or forms a ring with R 10 ; R 2 , R 3 , R 4 , R 5 , and R 6 are each independently H, lower alkyl, halo, nitro, OH, lower alkoxy, NH 2 , lower alkylamino, di(lower alkyl)amino, or two adjacent groups together form a saturated or unsaturated ring; or a pharmaceutically acceptable salt thereof.

  1式的化合物调节Rho C的活性：其中R是直接键，低碳基，—C（O）NH—或—NHC（O）—;Ar是芳基或杂环芳基，用R7，R8，R9和R10取代，其中R7，R8和R9各自独立地为H，卤素，低烷基，OH，低烷氧基，而R10为H，卤素，低烷基，OH，低烷氧基或与R1形成环；R1为H，低烷基或与R10形成环；R2，R3，R4，R5和R6各自独立地为H，低烷基，卤素，硝基，OH，低烷氧基，NH2，低烷基氨基，二（低烷基）氨基，或两个相邻的基团共同形成饱和或不饱和环；或其药学上可接受的盐。
• 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
  申请人：Spinks Daniel

  公开号：US20050154023A1

  公开（公告）日：2005-07-14

  The present invention relates to 1-arylsulfonyl-3-substituted indole or indoline derivatives having the general formula I wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R 6 -R 11 , are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.

  本发明涉及具有一般式I的1-芳基磺酰基-3-取代吲哚或吲哚啉衍生物，其中虚线表示可选键；n为0或1；m为0-5，而Ar、R6-R11在说明中定义。本发明还涉及包含所述衍生物的制药组合物，并且涉及使用这些1-芳基磺酰基-3-取代吲哚或吲哚啉衍生物治疗中枢神经系统疾病，如精神病、精神分裂症、躁郁症、抑郁症、神经系统疾病、认知增强、帕金森病、肌萎缩性侧索硬化症、阿尔茨海默病和亨廷顿病。
• Witt; Schneider, Chemische Berichte, 1901, vol. 34, p. 3172
  作者：Witt、Schneider

  DOI：——

  日期：——
• [EN] MODULATORS OF RHO C ACTIVITY<br/>[FR] MODULATEURS DE L'ACTIVITE DE RHO C
  申请人：ICONIX PHARM INC

  公开号：WO2003043578A2

  公开（公告）日：2003-05-30
• EP1453470A4
  申请人：——

  公开号：EP1453470A4

  公开（公告）日：2006-05-17